Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cameron J Turtle

Showing results (11-20 of 129) with videos related to

Pageof 13
Sort By:
American Journal of Hematology|February 21, 2019
Toxicities of CD19 CAR-T cell immunotherapyAlexandre V Hirayama, Cameron J Turtle
Bone Marrow Transplantation|August 22, 2019
Insight into mechanisms associated with cytokine release syndrome and neurotoxicity after CD19 CAR-T cell immunotherapyCassie K Chou, Cameron J Turtle
Human Gene Therapy|May 2, 2018
Driving CARs Across New BordersCameron J Turtle, Jennifer E Adair
Current Opinion in Immunology|January 18, 2011
Genetically retargeting CD8+ lymphocyte subsets for cancer immunotherapyCameron J Turtle, Stanley R Riddell
Expert Review of Hematology|June 21, 2016
Clinical trials of CD19-targeted CAR-modified T cell therapy; a complex and varied landscapeCameron J Turtle, David G Maloney
Drugs|January 23, 2017
Chimeric Antigen Receptor (CAR) T Cells: Lessons Learned from Targeting of CD19 in B-Cell MalignanciesKevin A Hay, Cameron J Turtle
CNS Drugs|November 3, 2018
Neurotoxicity Associated with CD19-Targeted CAR-T Cell TherapiesJuliane Gust, Agne Taraseviciute, Cameron J Turtle
Expert Review of Hematology|September 21, 2012
Augmentation of anti-tumor immunity by adoptive T-cell transfer after allogeneic hematopoietic stem cell transplantationMarie Bleakley, Cameron J Turtle, Stanley R Riddell
Expert Review of Hematology|October 23, 2024
Evolving strategies to overcome barriers in CAR-T cell therapy for acute myeloid leukemiaChanukya K Colonne, Erik L Kimble, Cameron J Turtle
Current Opinion in Immunology|July 24, 2012
Engineered T cells for anti-cancer therapyCameron J Turtle, Michael Hudecek, Michael C Jensen, et al.
Pageof 13

Showing results (11-20 of 129) with videos related to

Sort By:
Pageof 13
American Journal of Hematology|February 21, 2019
Toxicities of CD19 CAR-T cell immunotherapyAlexandre V Hirayama, Cameron J Turtle
Bone Marrow Transplantation|August 22, 2019
Insight into mechanisms associated with cytokine release syndrome and neurotoxicity after CD19 CAR-T cell immunotherapyCassie K Chou, Cameron J Turtle
Human Gene Therapy|May 2, 2018
Driving CARs Across New BordersCameron J Turtle, Jennifer E Adair
Current Opinion in Immunology|January 18, 2011
Genetically retargeting CD8+ lymphocyte subsets for cancer immunotherapyCameron J Turtle, Stanley R Riddell
Expert Review of Hematology|June 21, 2016
Clinical trials of CD19-targeted CAR-modified T cell therapy; a complex and varied landscapeCameron J Turtle, David G Maloney
Drugs|January 23, 2017
Chimeric Antigen Receptor (CAR) T Cells: Lessons Learned from Targeting of CD19 in B-Cell MalignanciesKevin A Hay, Cameron J Turtle
CNS Drugs|November 3, 2018
Neurotoxicity Associated with CD19-Targeted CAR-T Cell TherapiesJuliane Gust, Agne Taraseviciute, Cameron J Turtle
Expert Review of Hematology|September 21, 2012
Augmentation of anti-tumor immunity by adoptive T-cell transfer after allogeneic hematopoietic stem cell transplantationMarie Bleakley, Cameron J Turtle, Stanley R Riddell
Expert Review of Hematology|October 23, 2024
Evolving strategies to overcome barriers in CAR-T cell therapy for acute myeloid leukemiaChanukya K Colonne, Erik L Kimble, Cameron J Turtle
Current Opinion in Immunology|July 24, 2012
Engineered T cells for anti-cancer therapyCameron J Turtle, Michael Hudecek, Michael C Jensen, et al.
Pageof 13